Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Speciality Medicines Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹124
Per ShareLot Size
1000 Shares
Minimum Investment
₹1,24,000
Issue Size
₹29.14 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
49%
QIB Quota
2%
NII Quota
49%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
59.67%
Promoter Holding (Post-Issue)
43.26%
Issue Type
Book Building - SME
ISIN
INE0R0M01014
The Company is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.We offer a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases. Our products which are offered in such areas are available in a wide range of dosage forms like Tablets, Capsules, Cream, Syrups, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet and Suspension. We operate through two integrated business models: (a) Manufacturing, through contract manufacturing basis, of approved finished formulations and distribution internationally and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public issue of up to 23,50,000 equity shares of face value of Rs. 10/- each of Speciality Medicines Limited ("SML" or the "Company" or the "Issuer") for cash at a price of Rs. 124 per equity share including a share premium of Rs. 114 per equity share (the "Issue Price") aggregating to Rs. 29.14 Crores ("the Issue"), of which up to 1,50,000 equity shares of face value of Rs.10/- each for cash at a price of Rs. 124 per equity share including a share premium of Rs. 114 per equity share aggregating to Rs. 1.86 Crores will be reserved for subscription by market maker to the issue (the "Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. Net issue of 22,00,000 to be updated equity shares of face value of Rs. 10/- each at a price of Rs. 124 per equity share including a share premium of Rs. 114 per equity share aggregating to Rs. 27.28 Crores is herein after referred to as the "Net Issue". The issue and the net issue will constitute 26.75% and 25.04%, respectively, of the post issue paid up equity share capital of the company. The face value of the equity shares is Rs. 10/- each. Price Band: Rs. 124 per equity share of face value of Rs. 10 each. The floor price is 12.40 times of the face value. Bids can be made for a minimum of 2000 equity shares and in multiples of 1000 equity shares thereafter.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
India is the largest provider of generic drugs globally, accounting for approximately 20% of the global supply by volume and contributes over 60% of the global vaccine demand. As of 2024, India is home to over 3,000 pharmaceutical companies and more than 10,000 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States. This has positioned the country as a critical part of the global pharmaceutical supply chain, especially for regulated markets such as the United States, European Union, and Japan.
The Company was originally incorporated as "Speciality Medicines Private Limited" as a Private Limited Company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated February 05, 2021, issued by the Registrar of Companies, Central Registration Centre. Later on, pursuant to a special resolution passed by its Shareholders in the Extra-Ordinary General Meeting held on April 04, 2024, the Company was converted from a private limited company to public limited company and consequently, the name of the Company was changed from "Speciality Medicines Private Limited" to "Speciality Medicines Limited" and a fresh certificate of incorporation dated June 25, 2024 was issued to our Company by the Registrar of Companies, Central Registration Centre. The Corporate Identification Number of our Company is U85300GJ2021PLC120022.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.